汇宇制药-W
(688553)
| 流通市值：54.65亿 | | | 总市值：67.41亿 |
| 流通股本：5.07亿 | | | 总股本：6.26亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 551,856,179.99 | 269,206,581.35 | 998,144,952.02 | 741,750,405.84 |
| 营业总成本 | 471,782,101.01 | 241,878,348.21 | 923,789,392.55 | 685,551,126.24 |
| 其他经营收益 | | | | |
| 营业利润 | 48,022,067.02 | 15,990,634.05 | -66,224,823.77 | -77,308,939.17 |
| 利润总额 | 49,322,451.25 | 16,509,516.45 | -64,312,837.41 | -76,284,509.37 |
| 净利润 | 57,063,904.83 | 21,719,987.14 | -30,547,754.14 | -55,069,850.69 |
| 每股收益 | | | | |
| 其他综合收益 | -1,508,628.45 | 622,982.18 | -1,957,391.72 | -2,111,898.33 |
| 综合收益总额 | 55,555,276.38 | 22,342,969.32 | -32,505,145.86 | -57,181,749.02 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,379,172,969.74 | 3,300,019,544.8 | 3,172,647,770.55 | 3,076,352,843.48 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,825,150,339.79 | 1,828,552,778.27 | 1,846,851,657.39 | 1,799,884,807.16 |
| 资产总计 | 5,204,323,309.53 | 5,128,572,323.07 | 5,019,499,427.94 | 4,876,237,650.64 |
| 流动负债: | | | | |
| 流动负债合计 | 1,390,514,705.95 | 1,264,771,219.65 | 1,180,890,006.01 | 1,078,930,576.55 |
| 非流动负债: | | | | |
| 非流动负债合计 | 95,699,545.62 | 94,512,328.12 | 91,663,615.95 | 76,328,749.84 |
| 负债合计 | 1,486,214,251.57 | 1,359,283,547.77 | 1,272,553,621.96 | 1,155,259,326.39 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,729,944,027.31 | 3,780,688,229.17 | 3,758,196,107.46 | 3,730,907,553.04 |
| 股东权益合计 | 3,718,109,057.96 | 3,769,288,775.3 | 3,746,945,805.98 | 3,720,978,324.25 |
| 负债和股东权益合计 | 5,204,323,309.53 | 5,128,572,323.07 | 5,019,499,427.94 | 4,876,237,650.64 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 851,621,154.78 | 318,245,959.91 | 1,288,217,879.42 | 1,031,888,173.09 |
| 经营活动现金流出小计 | 760,100,464.81 | 298,079,378.8 | 1,197,704,433.28 | 1,000,719,839.81 |
| 经营活动产生的现金流量净额 | 91,520,689.97 | 20,166,581.1 | 90,513,446.14 | 31,168,333.28 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 197,649,962.9 | 78,304,634 | 687,482,786.28 | 583,495,601.6 |
| 投资活动现金流出小计 | 214,207,243.88 | 123,457,865.81 | 556,693,826.78 | 445,355,562.18 |
| 投资活动产生的现金流量净额 | -16,557,280.98 | -45,153,231.81 | 130,788,959.5 | 138,140,039.42 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 502,671,940 | 331,900,000 | 901,146,000 | 625,071,444.45 |
| 筹资活动现金流出小计 | 489,911,606.56 | 247,171,723.58 | 801,197,069.61 | 725,591,146.71 |
| 筹资活动产生的现金流量净额 | 12,760,333.44 | 84,728,276.42 | 99,948,930.39 | -100,519,702.26 |
| 汇率变动对现金及现金等价物的影响 | -2,655,828.92 | -1,818,039.13 | -726,383.54 | 3,909,781.69 |
| 现金及现金等价物净增加额 | 85,067,913.51 | 57,923,586.58 | 320,524,952.49 | 72,698,452.13 |
| 期末现金及现金等价物余额 | 2,462,837,112.52 | 2,435,692,785.59 | 2,377,769,199.01 | 2,129,942,698.64 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 85,067,913.51 | - | 320,524,952.49 | - |